Boxer Capital’s Climb Bio CLYM Stock Holding History

Boxer Capital’s Portfolio CLYM Stock Details CLYM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-2,603,190	Closed	-$13.3M	–	66
2024 Q3	$13.3M	Hold	2,603,190	–	–	0.65%	39
2024 Q2	$18.5M	Buy	+2,603,190	New	+$17.3M	0.97%	29

Other funds holding CLYM

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

ABG

Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Boxer Capital's CLYM Position: Q4 2024 in Review

Boxer Capital sold out of Climb Bio (CLYM) in Q4 2024, closing a stake of 2,603,190 shares — an estimated $13.3M sold.

Boxer Capital first reported a position in CLYM in Q2 2024 and held it in 2 quarters. The position peaked at $18.5M in Q2 2024. 80 funds tracked by Wall St. Rank hold CLYM as of Q4 2024.

Boxer Capital reported no remaining Climb Bio position as of Q4 2024 after selling out during the quarter.
Boxer Capital sold 2,603,190 Climb Bio shares in Q4 2024, an estimated $13.3M.
Boxer Capital first reported a position in Climb Bio in Q2 2024 and held it in 2 quarters.
Boxer Capital's Climb Bio position peaked at $18.5M in Q2 2024.
80 funds tracked by Wall St. Rank held Climb Bio as of Q4 2024.

Based on Boxer Capital's 13F filing for Q4 2024.